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Abstract We evaluated Clearline Inﬂuenza A/B/(H1N1)
2009, a new multi-line immunochromatographic assay for
rapid detection of antigens of inﬂuenza A (Flu A), B (Flu
B), and A(H1N1)2009 viruses. Clearline detected Flu A,
Flu B, and A(H1N1)2009 viruses with a detection limit of
4.6 9 103 to 7.5 9 104 pfu/assay. The sensitivity and
speciﬁcity of detection of inﬂuenza virus by Clearline,
using RT-PCR as reference standard, were determined
for A(H1N1)2009, Flu A, and Flu B, in nasopharyngeal
aspirate, nasopharyngeal swab, and self-blown nasal dis-
charge specimens. Sensitivity for nasopharyngeal aspirate
specimens was: A(H1N1)2009 = 97.3 %, Flu A = 94.5 %,
and Flu B = 96.8 %, and speciﬁcity was Flu A = 99.1 %
and Flu B = 100 %. Sensitivity for nasopharyngeal swab
specimens was: A(H1N1)2009 = 91.9 %, Flu A = 92.8 %,
and Flu B = 100 %, and speciﬁcity was Flu A = 98.2 %
and Flu B = 100 %. Sensitivity for self-blown nasal
discharge specimens was: A(H1N1)2009 = 75.7 %, Flu
A = 86.5 %, and Flu B = 76.2 %, and speciﬁcity was Flu
A = 98.4 % and Flu B = 100 %. Sensitivity and speciﬁc-
ity of Clearline were sufﬁcient for nasopharyngeal aspirate
and swab specimens. For self-blown nasal discharge
specimens, sensitivity was lower than for nasopharyngeal
aspirates and nasopharyngeal swabs. The sensitivity of
Clearline for A(H1N1)2009 was good even 6 h after the
onset of symptoms. These ﬁndings suggest that Clearline
may be useful for early clinical diagnosis of inﬂuenza.
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Introduction
Seasonal and pandemic inﬂuenza are a major burden on
health and the economy. New antivirals, for example
neuraminidase inhibitors, have recently become available
for management of inﬂuenza [1, 2]. Treatment and infec-
tion-control strategies are more effective when manage-
ment is started at an early stage of illness and epidemics, so
accurate and rapid diagnosis of inﬂuenza are very impor-
tant for appropriate use of antivirals and for infection
control. Although rapid inﬂuenza diagnostic tests (RIDTs)
help early diagnosis of inﬂuenza and also detect A(H1N1)
2009 virus as Flu A, RIDTs cannot distinguish A(H1N1)
2009 from seasonal Flu A and the sensitivity of currently
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available RIDTs was reported to be lower than for viral
culture or RT-PCR, especially during the A(H1N1)2009
virus pandemic [3–5]. In this study, we evaluated the
clinical usefulness of the Clearline Inﬂuenza A/B/
(H1N1)2009 test (Alere Medical, Tokyo, Japan), a new
multi-line immunochromatographic assay for rapid detec-
tion of antigens of the Flu A, Flu B, and A(H1N1)2009
viruses.
Materials and methods
Basic evaluation
Detection limit
Ten vaccine strains and clinical isolates of inﬂuenza
(Yokohama Institute of Public Health, Yokohama, Japan)
[6] were used in this evaluation (Table 1). Viral titer was
determined by plaque assays, and isolates were diluted
serially in phosphate-buffered saline. A 100-lL aliquot of
each viral suspension was mixed with 300 lL diluent,
provided in the Clearline kit, and the mixture was then
tested with Clearline. The detection limit was determined
on the basis of Clearline results for different dilutions of
each suspension.
Clinical evaluation
Clinical specimens
Three-hundred and thirty nasopharyngeal swab specimens
and 336 nasopharyngeal aspirate specimens were collected
simultaneously from 336 patients, including both children
and adults, with inﬂuenza-like illness (upper respiratory
symptoms and/or fever) at two hospitals and four clinics
(four pediatric, one internal medicine, and one pediatric/
internal medicine) in Japan during the 2010/2011 inﬂuenza
season (December 2010 to March 2011). Duration of fever
was recorded by interview with patients. Another set of 268
patients with inﬂuenza like illness (upper respiratory
symptoms and/or fever) was asked to blow nasal mucus
into a collection ﬁlm to furnish self-blown nasal discharge
specimens. The results from the two patient cohorts were
compared. The study protocol was approved by the ethics
committee of Eiju General Hospital. All subjects provided
informed consent to participate in this study.
Nasopharyngeal aspirate and self-blown nasal discharge
specimens were tested with Clearline and with Espline
inﬂuenza A&B–N (Fujirebio, Tokyo, Japan), without
dilution by viral transport media. These specimens were
sampled using swabs; the swabs were soaked in 1.5 mL
viral transport medium and stored at -80 C for RT-PCR
as the reference assay. One nasopharyngeal swab collected
from each patient was tested with Clearline.
Methods of measurement
Rapid diagnostic tests Clearline Inﬂuenza A/B/
(H1N1)2009 has three test lines, for differentiation of Flu
A, Flu B, and A(H1N1)2009 viruses, and a control line [7].
Testing was performed in accordance with the manufac-
turer’s instructions. A specimen-collection swab provided
in the kit was used to obtain the specimen. The swab
containing the specimen was placed directly in a dedicated
soft plastic tube containing 300 lL diluent provided in the
kit. The swab was then rotated at least 5 times, squeezed
against the interior wall of the tube, and pulled up while
squeezing to extract the liquid from the swab. A test strip
was inserted into the tube to start the reaction. After
10–15 min, the appearance of red–purple lines on the strip
was assessed in accordance with the criteria in the manu-
facturer’s instructions.
Espline Inﬂuenza A&B–N is a lateral ﬂow RIDT using
enzyme immunoassay to differentiate Flu A and Flu B [8].
Testing was performed in accordance with the manufac-
turer’s instructions.
RT-PCR The specimens were subjected to multiplex RT-
PCR. A PCR sample was extracted from 200 lL of each
stored suspension by use of the QIAamp Min Elute Virus
Spin Kit (Qiagen, Valencia, CA, USA) in accordance with
the manufacturer’s instructions. The multiplex RT-PCR
was performed with Seeplex RV 12 ACE Detection kit and
the combined Supplement procedure for detection and
characterization of swine H1 inﬂuenza A virus provided by
manufacturer (Seegene, Seoul, Korea), to detect A(H1N1)
2009, Flu A, and Flu B [9–11]. The HA gene of Flu A virus
other than A(H1N1)2009 virus was detected, by use of
real-time RT-PCR, to characterize subtype [12].
Table 1 Detection limit of Clearline for inﬂuenza virus strains
Virus strain Detection limit
(pfu/assay)
A/California/7/2009 (H1N1)2009 5.3 9 104
A/Yokohama/29/2010 (H1N1)2009 5.6 9 103
A/Yokohama/1000/2009 (H1N1)2009 4.6 9 103
A/New Caledonia/20/99 (H1N1) 5.8 9 104
A/Yokohama/119/2009 (H1N1) 2.8 9 104
A/Yokohama/22/2002 (H1N2) 3.2 9 104
A/Hiroshima/52/2005 (H3N2) 2.1 9 104
A/Yokohama/72/2010 (H3N2) 7.5 9 104
B/Shanghai/361/2002 (Yamagata lineage) 1.7 9 104
B/Malaysia/2506/2004 (Victoria lineage) 1.4 9 104
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Statistical analysis
SPSS statistics 20 (Japan IBM, Japan) was used for sta-
tistical analysis. A p value of less than 0.05 was considered
statistically signiﬁcant.
Results
Basic evaluation
Detection limit of Clearline
The detection limit of Clearline was 4.6 9 103 to 7.5 9
104 pfu/assay for ten inﬂuenza virus strains including
A(H1N1)2009 (Table 1).
Clinical evaluation
Sensitivity and speciﬁcity
Among the 336 nasopharyngeal aspirate specimens, mul-
tiplex RT-PCR detected A(H1N1)2009 virus in 149 spec-
imens, Flu A strains other than A(H1N1)2009 in 73
specimens, and Flu B in 31 specimens. All Flu A strains
other than A(H1N1)2009 were conﬁrmed to be H3 strains
(Flu A (H3)).
As Tables 2 and 3 show, the sensitivity of Clearline
compared with multiplex RT-PCR for A(H1N1)2009, Flu
A (H3), and Flu B was 97.3 % (145/149), 94.5 % (69/73),
and 96.8 % (30/31), respectively. The speciﬁcity was
99.1 % (113/114) for type A inﬂuenza virus and 100 %
(305/305) for Flu B. Among RT-PCR-conﬁrmed A(H1N1)
2009-positive specimens, nine samples were positive only
on the A(H1N1)2009 test line of Clearline but negative on
the Flu A test line. The corresponding sensitivity of Espline
for A(H1N1)2009, Flu A (H3), and Flu B was 91.9 % (137/
149), 94.5 % (69/73), and 100 % (31/31), respectively, and
the speciﬁcity was 100 % (114/114) for type A inﬂuenza
virus and 99.0 % (302/305) for Flu B.
Nasopharyngeal swabs were collected from 330 patients
simultaneously with nasopharyngeal aspiration. Tables 2
and 3 show the performance of Clearline for nasopharyn-
geal swabs compared with results from multiplex RT-PCR
of nasopharyngeal aspirates. The sensitivity of Clearline
for A(H1N1)2009, Flu A (H3), and Flu B on nasopharyn-
geal swabs was 91.9 % (137/149), 92.8 % (64/69), and
100 % (31/31), respectively; speciﬁcity was 98.2 % (110/
112) for type A inﬂuenza virus and 100 % (299/299) for
Flu B.
Among 268 self-blown nasal discharge specimens,
multiplex RT-PCR detected A(H1N1)2009 in 103 speci-
mens, Flu A other than A(H1N1)2009 in 37 specimens, and
Flu B in 21 specimens. All Flu A viruses other than
A(H1N1)2009 were conﬁrmed to be H3 strains (Flu A
(H3)). Tables 2 and 3 list the performance of the assays
for self-blown nasal discharge specimens. The sensitivity
of Clearline compared with multiplex RT-PCR for
A(H1N1)2009, Flu A (H3), and Flu B was 75.7 % (78/103),
86.5 % (32/37), and 76.2 % (16/21), respectively, and
the speciﬁcity was 98.4 % (126/128) for type A inﬂuenza
virus and 100 % (247/247) for Flu B. Among RT-PCR-
conﬁrmed A(H1N1)2009-positive specimens, eighteen
specimens were positive on the A(H1N1)2009 test line of
Clearline only but negative on the Flu A test line. The
corresponding sensitivity and speciﬁcity for Espline com-
pared with multiplex RT-PCR were almost same as for
Clearline. For both Clearline and Espline, sensitivity for
self-blown nasal discharge specimens for A(H1N1) 2009
was lower than for nasopharyngeal aspirate and nasopha-
ryngeal swab specimens (p\ 0.001 for each).
Effect of time after onset of fever on the sensitivity
of Clearline
The effect of time after onset of fever on the sensitivity of
Clearline and Espline is listed in Table 4 for nasopharyn-
geal aspirates and swabs conﬁrmed positive by multiplex
RT-PCR, for the 248 specimens for which time from onset
of fever was known. The sensitivity of Clearline and
Espline was more than 85 % for specimens collected more
than 6 h after onset. Within 6 h of onset, the sensitivity of
Clearline for A(H1N1)2009 was high (100 % for naso-
pharyngeal aspirate and 88.2 % for nasopharyngeal swab)
although the sensitivity of Clearline for Flu A(H3) and of
Espline for Flu A(H3) and A(H1N1)2009 was relatively
low (80.0–82.4 %).
Discussion
The performance of RIDTs for patients with inﬂuenza
depends on viral load [13, 14]. Detection limits of currently
available RIDTs have been reported to differ widely among
viral strains or kits, ranging from approximately 103 to
105 pfu/assay or 103 to[106 TCID50/assay for seasonal
inﬂuenza, A(H1N1)2009, and avian inﬂuenza [6, 15]. In
this study, the detection limits of Clearline were approxi-
mately 104 pfu/assay for Flu A and Flu B, and from
4.6 9 103 to 5.3 9 104 pfu/assay for A(H1N1)2009.
The detection limit of Clearline was fairly consistent,
irrespective of viral strain, and was equivalent to those
previously reported for conventional diagnostic kits [6].
In our previously study, the sensitivity of Espline for
nasopharyngeal aspirates compared with viral culture was
95.4 % (125/131) for Flu A (not including A(H1N1)2009)
J Infect Chemother (2013) 19:633–638 635
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and 91.2 % (52/57) for Flu B [8]. Cheng et al. [13] reported
low sensitivity of Espline for A(H1N1)2009(62 %), but the
specimens in their study were diluted with viral transport
medium. In our study, the sensitivity of Clearline and
Espline for Flu A (H3) in nasopharyngeal aspirates using
multiplex RT-PCR as reference standard was 94.5 % (69/73)
and 94.5 % (69/73), respectively, which was high, and
similar to that in our previous report. The specimens were
tested directly, without dilution with viral transport med-
ium. If test methods are adjusted, sensitivity of RIDTs may
Table 2 Comparison of Clearline and Espline with multiplex RT-PCR for 3 types of specimen
Inﬂuenza detection by multiplex RT-PCR
Type A Type B
(H1N1)2009 positive A(H3) positive Negative Positive Negative
Nasopharyngeal aspirate (n = 336)
Clearline
Positive 145 69 1 30 0
Negative 4 4 113 1 305
Total 149 73 114 31 305
Espline
Positive 137 69 0 31 3
Negative 12 4 114 0 302
Total 149 73 114 31 305
Nasopharyngeal swab (n = 330)a
Clearline
Positive 137 64 2 31 0
Negative 12 5 110 0 229
Total 149 69 112 31 229
Self-blown nasal discharge (n = 268)
Clearline
Positive 78 32 2 16 0
Negative 25 5 126 5 247
Total 103 37 128 21 247
Espline
Positive 75 36 0 16 0
Negative 28 1 128 5 247
Total 103 37 128 21 247
a Compared with multiplex RT-PCR results for nasopharyngeal aspirates
Table 3 Sensitivity and speciﬁcity of Clearline and Espline for 3 types of specimen
Specimen types RIDTs Sensitivity Speciﬁcity
A(H1N1)2009 A(H3) Type B Type A Type B
Nasopharyngeal
Aspirate
(n = 336)
Clearline 97.3 % (94.7–99.9) 94.5 % (86.6–98.5) 96.8 % (83.3–99.9) 99.1 % (97.4–100) 100.0 % (100–100)
Espline 91.9 % (87.6–96.3) 94.5 % (86.6–98.5) 100.0 % (88.8–100) 100.0 % (100–100) 99.0 % (97.9–100)
Nasopharyngeal
swab
(n = 330)
Clearline 91.9 % (87.6–96.3) 92.8 % (83.9–96.3) 100.0 % (100–100) 98.2 % (95.8–100) 100.0 % (100–100)
Self-blown nasal
discharge
(n = 268)
Clearline 75.7 % (67.4–84.0)* 86.5 % (71.2–95.5) 76.2 % (52.8–91.8) 98.4 % (96.3–100) 100.0 % (100–100)
Espline 72.8 % (64.2–81.4)* 97.3 % (85.8–99.9) 76.2 % (52.8–91.8) 100.0 % (100–100) 100.0 % (100–100)
Ranges in parentheses are 95 % conﬁdence intervals
* p\ 0.001: compared with both nasopharyngeal aspirate and swab specimens (chi-squared test)
636 J Infect Chemother (2013) 19:633–638
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be sufﬁcient for practical use. The corresponding ﬁgures
for A(H1N1)2009 were 97.3 % (145/149) for Clearline and
91.9 % (137/149) for Espline. Although these values are
not statistically signiﬁcantly different, direct comparison
shows Clearline was able to detect more A(H1N1)2009
cases than Espline (nine cases were positive by Clearline
but negative by Espline, and one was negative by Clearline
but positive by Espline) because of the high sensitivity of
the A(H1N1)2009 test line of Clearline. Choi et al. [7] also
reported relatively high sensitivity of the A(H1N1)2009
test line compared with the Flu A test line for nasopha-
ryngeal swab specimens. If the A(H1N1)2009 line is neg-
ative for specimens with positive Flu A test line, this may
suggest positive Flu A(H3) during interpandemics.
In this study, we collected two types of specimen
simultaneously from 330 patients, and compared the sen-
sitivity directly for nasopharyngeal aspirations and naso-
pharyngeal swabs. The sensitivity of Clearline was no
different for nasopharyngeal swab and nasopharyngeal
aspiration specimens.
Self-blown nasal discharge is a type of specimen
recently approved for use in RIDTs in Japan. This type of
specimen may reduce the burden of sampling—it is pos-
sible to collect specimens without medical equipment and
from patients who must avoid injury to the nasal cavity.
One limitation of this study is that self-blown nasal dis-
charge specimens were obtained from a patient population
different from that from which the nasopharyngeal aspi-
rates and swabs were obtained, making direct comparison
of sensitivity between specimen types somewhat more
difﬁcult. Although sensitivity of both Clearline and Espline
for self-blown nasal discharges was more than 72 %, this
was lower than for nasopharyngeal aspirates and swabs
(p\ 0.001). Physicians should be aware that the use of
self-blown nasal discharge specimens may reduce the
sensitivity of the assay, and should conduct specimen
collection carefully to obtain an ample volume.
This study was conducted at four pediatric sites, one
internal medicine site, and one pediatric/internal medicine
site. Sensitivity and speciﬁcity were not statistically dif-
ferent among the 3 types of site. Further study may be
necessary to determine whether patient age affects the
sensitivity of RIDTs.
During the A(H1N1) inﬂuenza pandemic in 2009, deaths
due to inﬂuenza were less common in Japan than in other
countries. Use of anti-inﬂuenza agents from an early stage
of infection is believed to be one reason for this lower
mortality in Japan [16]. Analysis of Japanese pediatric
patients hospitalized for respiratory disorders due to
A(H1N1)2009 in this pandemic revealed 87.5 % developed
dyspnea within 24 h of onset of fever [17]. It is recom-
mended antivirals are started as soon as possible for
patients with severe or progressive inﬂuenza, before the
result from inﬂuenza testing is received [2]. It is, thus,
important to promptly and correctly diagnose inﬂuenza and
start treatment with anti-inﬂuenza agents [16]. However,
there was a tendency toward lower accuracy of RIDTs on
the ﬁrst day of illness [5]. Our results showed sensitivity
within 6 h of the onset of fever was relatively low for
A(H1N1)2009 for Espline and for Flu A(H3) but that the
sensitivity of Clearline for A(H1N1)2009 was high within
6 h of onset and for specimens collected after 6 h from
onset. High sensitivity of the A(H1N1)2009 test line may
contribute to the sensitivity within 6 h of onset of fever.
The cost of Clearline is equivalent to that of the other
tests, when comparing the list prices (the price for Clear-
line is within the range of list price for other test,
approximately US$ 11–16 per test; exchange rate ¥80/
US$). So Clearline has the value of detecting the
A(H1N1)2009 virus separately from the Flu A virus at a
cost equivalent to those of the other conventional tests.
In conclusion, Clearline may be expected to help phy-
sicians to diagnose inﬂuenza promptly and detect
A(H1N1)2009 virus separately from the Flu A(H3) virus in
the clinical setting. Further studies may be necessary to
evaluate the factors that affect the sensitivity of RIDTs.
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Table 4 Effect of duration of fever on sensitivity of Clearline and Espline (%)
Duration of
fever (h)
Nasopharyngeal aspirate Nasopharyngeal swab
Clearline Espline Clearline
A(H1N1)2009 Type A(H3) Type B A(H1N1)2009 Type A(H3) Type B A(H1N1)2009 Type A(H3) Type B
*6 100 (17/17) 80.0 (8/10) 100 (3/3) 82.4 (14/17) 80.0 (8/10) 100 (3/3) 88.2 (15/17) 80.0 (8/10) 100 (3/3)
*12 95.7 (22/23) 85.7 (12/14) 100 (3/3) 91.3 (21/23) 92.9 (13/14) 100 (3/3) 91.3 (21/23) 92.9 (13/14) 100 (3/3)
*24 96.0 (72/75) 97.2 (35/36) 90.0 (9/10) 93.3 (70/75) 97.2 (35/36) 100 (10/10) 94.6 (71/75) 94.4 (34/36) 100 (10/10)
*48 100 (24/24) 100 (9/9) 100 (14/14) 95.8 (23/24) 100 (9/9) 100 (14/14) 91.7 (22/24) 100 (9/9) 100 (14/14)
49* 100 (7/7) 100 (2/2) 100 (1/1) 100 (7/7) 100 (2/2) 100 (1/1) 85.7 (6/7) 100 (2/2) 100 (1/1)
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